Recent advances in delivery of drug–nucleic acid combinations for cancer treatment

Li, Jing; Wang, Yan; Zhu, Yu; Oupický, David

doi:10.1016/j.jconrel.2013.04.010

Cited by 184 publications

(129 citation statements)

References 84 publications

Supporting

Mentioning

128

Contrasting

Order By: Relevance

“…23 Multifunctional nanocarriers with active targeting, cell membrane translocation and pH-triggered payload release were developed for co-delivery of nucleic acids with traditional cytotoxic drugs. 24,25 These nanocarriers showed improved cellular uptake of nucleic acids and cytotoxic drugs, leading to the enhanced cytotoxicity against drug-resistant cancer cells. Applications of multifunctional nanocarriers to drug-sensitive cancer treatment have also burst onto a scene with better therapeutic efficacy.…”

Section: Introductionmentioning

confidence: 99%

Rational design of multifunctional micelles against doxorubicin-sensitive and doxorubicin-resistant MCF-7 human breast cancer cells

Hong

Shi

Qiao

et al. 2017

IJN

View full text Add to dashboard Cite

Even though a tremendous number of multifunctional nanocarriers have been developed to tackle heterogeneous cancer cells, little attention has been paid to elucidate how to rationally design a multifunctional nanocarrier. In this study, three individual functions (active targeting, stimuli-triggered release and endo-lysosomal escape) were evaluated in doxorubicin (DOX)-sensitive MCF-7 cells and DOX-resistant MCF-7/ADR cells by constructing four kinds of micelles with active-targeting (AT-M), passive targeting, pH-triggered release ( pH T-M) and endo-lysosomal escape ( endo E-M) function, respectively. AT-M demonstrated the strongest cytotoxicity against MCF-7 cells and the highest cellular uptake of DOX due to the folate-mediated endocytosis. However, AT-M failed to exhibit the best efficacy against MCF-7/ADR cells, while endo E-M exhibited the strongest cytotoxicity against MCF-7/ADR cells and the highest cellular uptake of DOX due to the lowest elimination of DOX from the cells. This was attributed to the carrier-facilitated endo-lysosomal escape of DOX, which avoided exocytosis by lysosome secretion, resulting in an effective accumulation of DOX in the cytoplasm. The enhanced elimination of DOX from the MCF-7/ADR cells also accounted for the remarkable decrease in cytotoxicity against the cells of AT-M. Three micelles were further evaluated with MCF-7 cells and MCF-7/ADR-resistant cells xenografted mice model. In accordance with the in vitro results, AT-M and endo E-M demonstrated the strongest inhibition on the MCF-7 and MCF-7/ADR xenografted tumor, respectively. Active targeting and active targeting in combination with endo-lysosomal escape have been demonstrated to be the primary function for a nanocarrier against doxorubicin-sensitive and doxorubicin-resistant MCF-7 cells, respectively. These results indicate that the rational design of multifunctional nanocarriers for cancer therapy needs to consider the heterogeneous cancer cells and the primary function needs to be integrated to achieve effective payload delivery.

show abstract

Section: Introductionmentioning

confidence: 99%

Rational design of multifunctional micelles against doxorubicin-sensitive and doxorubicin-resistant MCF-7 human breast cancer cells

Hong

Shi

Qiao

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…Researchers recently reported the efficacy of multidrug delivery using nanoparticles in effectively mediating resistance in relapsing cancers and to improve triple-negative breast cancer treatment [27]. For example, delivery of layer-by-layer small interfering RNA (siRNA) and doxorubicin for breast cancer therapy.…”

Section: Simultaneous Delivery Of Two Drugsmentioning

confidence: 99%

Nanomedicine - the Future of Cancer Treatment: A Review

Sebastian¹

2017

JCPCR

View full text Add to dashboard Cite

Conventional cancer therapies are limited to surgery, radiation, and chemotherapy. Conventional treatments come with significant adverse effects. Modern cancer treatments focus on precise drug delivery to the cancer tissues and minimize adverse effects on healthy cells. Researchers have been working on an improved technique for delivering chemotherapeutic agents precisely at the molecular level in the tumor tissue. It has led to the use of nanotechnology in cancer treatment. Nanotechnology is the science and engineering of controlling matter, at the molecular scale, to create devices with novel chemical, physical and biological properties. Nanoscale objects are used themselves or as part of larger devices containing multiple nanoscale objects. Almost every field of Biosciences uses nanotechnology and all of which have an impact on biomedicine. It has the potential to change the current methods to diagnose and treat cancer. There has been real progress in translating nano-based cancer therapies and diagnostics into the clinic, and much more are in development. Nanoparticles are mainly used as nanocarriers to deliver the cytotoxic drugs to the tumor tissue. Use of nanoparticles is based on different concepts of pharmacology. Nanomedicine also is utilized to deliver multiple drugs at the cancer site at the same time for a better cytotoxic effect. CytImmune Sciences is a developing field of nanomedicine for targeted chemotherapy method. They selectively deliver the drug at the cancer site because of the increased permeability of the blood vessels at the tumor site. This article reviews various nanomedicine-based cancer therapeutics.

show abstract

“…11 Previous research has shown that decreasing the expression level of Bcl-2 by the siRNA technique could efficiently trigger the apoptosis of cancer cells. 12,13 More importantly, the combination of chemotherapy and gene therapy such as Bcl-2 siRNA has been demonstrated to enhance the efficacy and improve the therapeutic outcome, [14][15][16][17] owing to the synergistic anticancer activity or enhanced sensitivity to chemotherapeutics.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of cell proliferation through an ATP-responsive co-delivery system of doxorubicin and Bcl-2 siRNA

Zhang¹,

Wang²,

Chen³

et al. 2017

IJN

View full text Add to dashboard Cite

Herein, DNA duplex was constructed through the hybridization of adenosine triphosphate (ATP)-responsive aptamer and its cDNA in which GC-rich motif could be used to load doxorubicin (DOX), and then, cationic polymer PEI25K was used as a carrier to simultaneously condense DOX-Duplex and Bcl-2 siRNA to prepare the ternary nanocomplex polyethylenimine (PEI)/DOX-Duplex/siRNA. The ATP concentration gradient between the cytosol and extracellular environment could achieve the stable loading of DOX in duplex and the rapid drug release in an ATP-responsive manner. Using human prostate tumor cell line PC-3 as a model, an obvious induction of cell proliferation could be detected with a cell viability of 53.3%, which was stronger than single cargo delivery, indicating the synergistic effect between these two components. The enhanced anti-proliferative effect of ternary nanocomplex could be attributed to the improved induction of cell apoptosis in a mitochondria-mediated pathway and cell-cycle arrest at the G2 phase. Overall, the ATP-responsive nanocarrier for co-delivering DOX and Bcl-2 siRNA has been demonstrated to be a smart delivery system with favorable anti-proliferative effect, especially for solving the multidrug resistance of tumors.

show abstract

Recent advances in delivery of drug–nucleic acid combinations for cancer treatment

Cited by 184 publications

References 84 publications

Rational design of multifunctional micelles against doxorubicin-sensitive and doxorubicin-resistant MCF-7 human breast cancer cells

Rational design of multifunctional micelles against doxorubicin-sensitive and doxorubicin-resistant MCF-7 human breast cancer cells

Nanomedicine - the Future of Cancer Treatment: A Review

Inhibition of cell proliferation through an ATP-responsive co-delivery system of doxorubicin and Bcl-2 siRNA

Contact Info

Product

Resources

About